European CHMP recommends approval of selinexor (Nexpovio) for treatment of relapsed and refractory multiple myeloma

Selinexor is a CRM1 nuclear export inhibitor which inhibits export of tumour suppressor proteins from the nucleus, resulting in cell apoptosis. It is intended to be licensed in combination with dexamethasone in adults who have received at least four prior therapies.

Source:

European Medicines Agency